Emilie M.J. van Brummelen - Publications, H-index & Citations

Back

Emilie M.J. van Brummelen

Leiden University

22H-index

65Paper Count

4.5KCitation Count

Published Papers 20

Publication Date

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

FUTURE ONCOLOGY

IF2.6

2024-09-17

OAAI

Sonneveld, Pieter; Dimopoulos, Meletios A.; Boccadoro, Mario; Quach, Hang; Ho, P. Joy; Beksac, Meral; Hulin, Cyrille; Antonioli, Elisabetta; Leleu, Xavier; Mangiacavalli, Silvia; Perrot, Aurore; Cavo, Michele; Belotti, Angelo; Broijl, Annemiek; Gay, Francesca; Mina, Roberto; van de Donk, Niels W. C. J.; Katodritou, Eirini; Schjesvold, Fredrik; Balari, Anna Sureda; Rosinol, Laura; Delforge, Michel; Roeloffzen, Wilfried; Silzle, Tobias; Vangsted, Annette; Einsele, Hermann; Spencer, Andrew; Hajek, Roman; Jurczyszyn, Artur; Lonergan, Sarah; Ahmadi, Tahamtan; Liu, Yanfang; Wang, Jianping; Vieyra, Diego; van Brummelen, Emilie M. J.; Vanquickelberghe, Veronique; Sitthi-Amorn, Anna; de Boer, Carla J.; Carson, Robin; Rodriguez-Otero, Paula; Blade, Joan; Moreau, Philippe

Save

Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's Disease

JOURNAL OF PARKINSONS DISEASE

IF5

2024-08-22

OAAI

Eijsvogel, Pepijn P. N. M.; Borghans, Laura G. J. M.; Prins, Samantha; Moss, Laurence; van Kraaij, Sebastiaan J. W.; van Brummelen, Emilie; Klaassen, Erica; Martin, Renee S.; Bautista, Edgar; Ford, Anthony P.; Kremer, Philip H. C.; Groeneveld, Geert Jan; Vargas, Gabriel A.

Save

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-01-25

106

OAAI

Sonneveld, Pieter; Dimopoulos, Meletios A.; Boccadoro, Mario; Quach, Hang; Ho, P. Joy; Beksac, Meral; Hulin, Cyrille; Antonioli, Elisabetta; Leleu, Xavier; Mangiacavalli, Silvia; Perrot, Aurore; Cavo, Michele; Belotti, Angelo; Broijl, Annemiek; Gay, Francesca; Mina, Roberto; Nijhof, Inger S.; van de Donk, Niels W. C. J.; Katodritou, Eirini; Schjesvold, Fredrik; Sureda Balari, Anna; Rosinol, Laura; Delforge, Michel; Roeloffzen, Wilfried; Silzle, Tobias; Vangsted, Annette; Einsele, Hermann; Spencer, Andrew; Hajek, Roman; Jurczyszyn, Artur; Lonergan, Sarah; Ahmadi, Tahamtan; Liu, Yanfang; Wang, Jianping; Vieyra, Diego; van Brummelen, Emilie M. J.; Vanquickelberghe, Veronique; Sitthi-Amorn, Anna; de Boer, Carla J.; Carson, Robin; Rodriguez-Otero, Paula; Blade, Joan; Moreau, Philippe

Save

Objective Monitoring of Facioscapulohumeral Dystrophy During Clinical Trials Using a Smartphone App and Wearables: Observational Study

JMIR FORMATIVE RESEARCH

IF2.1

2022-09-13

OAAI

Maleki, Ghobad; Zhuparris, Ahnjili; Koopmans, Ingrid; Doll, Robert J.; Voet, Nicoline; Cohen, Adam; van Brummelen, Emilie; Groeneveld, Geert Jan; De Maeyer, Joris

Save

Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds

FRONTIERS IN ONCOLOGY

IF3.3

2022-08-29

OAAI

Radanovic, Igor; Klarenbeek, Naomi; Rissmann, Robert; Groeneveld, Geert Jan; van Brummelen, Emilie M. J.; Moerland, Matthijs; Bosch, Jacobus J.

Save

A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine

MOVEMENT DISORDERS

IF7.6

2022-04-15

OAAI

Yu, Hui Jing; Thijssen, Eva; van Brummelen, Emilie; van Der Plas, Johan L.; Radanovic, Igor; Moerland, Matthijs; Hsieh, Eric; Groeneveld, Geert Jan; Dodart, Jean-Cosme

Save

Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients

PARKINSONISM & RELATED DISORDERS

IF3.4

2022-04-01

OAAI

Thijssen, Eva; Den Heijer, Jonas M.; Puibert, David; Van Brummelen, Emilie M. J.; Naranda, Tatjana; Jan Groeneveld, Geert

Save

A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009

MOVEMENT DISORDERS

IF7.6

2022-01-20

OAAI

Thijssen, Eva; Heijer, Jonas; Puibert, David; Moss, Laurence; Lei, Mingzu; Hasegawa, David; Keum, Kyo; Mochel, Ken; Sharaf, Mohammed Ezzeldin; Alfredson, Tom; Zeng, Wenxiang; Brummelen, Emilie; Naranda, Tatjana; Groeneveld, Geert Jan

Save

A phase I, randomized, double-blind, placebo-controlled, single-and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Na(v)1.8 inhibitor, in healthy adults

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-12-27

OAAI

Hijma, Hemme J.; van Brummelen, Emilie M. J.; Siebenga, Pieter S.; Groeneveld, Geert Jan

Save

Healthy volunteers in first-in-human oncology drug development for small molecules

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-10-19

OAAI

de Las Heras, Begona; Bouyoucef-Cherchalli, Dalila; Reeve, Lesley; Reichl, Andreas; Mandarino, Debra; Flach, Stephen; Vidal, Laura; van Brummelen, Emilie M. J.; Steeghs, Neeltje

Save

First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-07-16

OAAI

Moss, Laurence M.; Berends, Cecile L.; van Brummelen, Emilie M. J.; Kamerling, Ingrid M. C.; Klaassen, Erica S.; Bergmann, Kirsten; Ville, Vanessa; Juarez-Perez, Victor; Benichou, Annie-Claude; Groeneveld, Geert Jan

Save

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-05-14

OAAI

Mellion, Michelle L.; Ronco, Lucienne; Berends, Cecile L.; Pagan, Lisa; Brooks, Sander; van Esdonk, Michiel J.; van Brummelen, Emilie M. J.; Odueyungbo, Adefowope; Thompson, Lorin A.; Hage, Michelle; Badrising, Umesh A.; Raines, Shane; Tracewell, William G.; van Engelen, Baziel; Cadavid, Diego; Groeneveld, Geert J.

Save

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

BRITISH JOURNAL OF CANCER

IF6.8

2020-03-09

OAAI

van Geel, Robin M. J. M.; van Brummelen, Emilie M. J.; Eskens, Ferry A. L. M.; Huijberts, Sanne C. F. A.; de Vos, Filip Y. F. L.; Lolkema, Martijn P. J. K.; Devriese, Lot A.; Opdam, Frans L.; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin D. R.; Beijnen, Jos H.; Bernards, Rene; Schellens, Jan H. M.

Save

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2019-12-20

OAAI

Van der Plas, Johan L.; Verdijk, Pauline; Van Brummelen, Emilie M. J.; Jeeninga, Rienk E.; Roestenberg, Meta; Burggraaf, Jacobus; Kamerling, Ingrid M. C.

Save

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

INVESTIGATIONAL NEW DRUGS

IF2.7

2019-05-07

OAAI

van Brummelen, Emilie M. J.; Levchenko, Evgeny; Domine, Manuel; Fennell, Dean A.; Kindler, Hedy L.; Viteri, Santiago; Gadgeel, Shirish; Garrido Lopez, Pilar; Kostorov, Vladimir; Morgensztern, Daniel; Orlov, Sergey; Zauderer, Marjorie G.; Vansteenkiste, Johan F.; Baker-Neblett, Katherine; Vasquez, James; Wang, Xiaowei; Bellovin, David, I; Schellens, Jan H. M.; Yan, Li; Mitrica, Ionel; DeYoung, M. Phillip; Trigo, Jose

Save

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

ANNALS OF ONCOLOGY

IF65.4

2017-05-01

191

OAAI

Ott, P. A.; Piha-Paul, S. A.; Munster, P.; Pishvaian, M. J.; Van Brummelen, E. M. J.; Cohen, R. B.; Gomez-Roca, C.; Ejadi, S.; Stein, M.; Chan, E.; Simonelli, M.; Morosky, A.; Saraf, S.; Emancipator, K.; Koshiji, M.; Bennouna, J.

Save

Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1 positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Rugo, H. S.; Delord, J-P; Im, S-A; Ott, P. A.; Piha-Paul, S. A.; Bedard, P. L.; Sachdev, J.; Le Tourneau, C.; van Brummelen, E.; Varga, A.; Saraf, S.; Pietrangelo, D.; Karantza, V.; Tan, A.

Save

Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Hsu, C.; Lee, S. H.; Ejadi, S.; Even, C.; Cohen, R.; Le Tourneau, C.; Mehnert, J.; Algazi, A.; Van Brummelen, E.; Yuan, S. S.; Thanigaimani, P.; Cheng, J.; Hansen, A.

Save

Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Ott, P. A.; Piha-Paul, S. A.; Munster, P.; Pishvaian, M. J.; Van Brummelen, E.; Cohen, R.; Gomez-Roca, C.; Ejadi, S.; Stein, M.; Chan, E.; Simonelli, M.; Morosky, A.; Yuan, S. S.; Koshiji, M.; Bennouna, J.

Save

Clinical evidence of intra-tumoral immune activation and tumor targeting with RG7813, a CEA-targeted engineered IL-2 immunocytokine

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Tabernero, J.; Homicsko, K.; Schellens, J. H.; Hoekstra, O.; Van der Veen, L.; Melero, I.; Argiles, G.; Mau-Sorensen, M.; Angevin, E.; Joensuu, H.; Van Brummelen, E.; Menke-van der Houven van Oordt, C. W.; Nayak, T.; Romagnoli, S.; Reis, B.; Brossard, S. Soehrman; Evers, S.; Saro, J.; Verheul, H.; Lassen, U.

Save

Research Directions